Literature DB >> 521493

C3d antiglobulin haemagglutination of human red blood cells. A demonstration of two types of cell-bound C3d by means of typsin digestion.

T C Hsu, J Steinberg, A Sawitsky.   

Abstract

Washed human red blood cells from blood collected in EDTA were tested by Auto-Analyzer for a percentage of maximum antiglobulin haemagglutination (AH) using monospecific antisera to human C3d and C3c. The cells from normal persons were found to be agglutinated by anti-C3d but not by anti-C3c. To a fixed dilution of antiserum, the normal C3d AH values (X +/- 2 SD) were 34 +/- 19% for adult cells (n = 29) and 14 +/- 19% for cord cells (n = 19); the difference was significant (P less than 0.0001). By pretreatment of these cells with trypsin the C3d AH was either completely abolished or markedly reduced. Its difference between the adult and cord cells was eliminated as the observed values were 4 +/- 7% and 3 +/- 4% respectively (P = 0.15). The supernatant fluid of cell-trypsin mixture, treated with trypsin inhibitors, was found to be inhibitory to C3d AH but not to C3c AH. In contrast, the AH of C3d-coated red blood cells resulting from complement fixation in vivo (ie, cold agglutinin disease) or in vitro (eg, sucrose water reaction) was resistant to trypsin treatment. The difference between the trypsin-sensitive and trypsin-resistant cell-bound C3d is postulated to be at its attachment mechanism to the cell membranes. In addition, both the advantage and limitation of using trypsinised cells for C3d antiglobulin tests are demonstrated.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 521493      PMCID: PMC1145882          DOI: 10.1136/jcp.32.10.1009

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  Instrumented PVP-augmented antiglobulin tests. II. Evaluation of acquired hemolytic anemia.

Authors:  T C Hsu; R E Rosenfield; P Burkart; K Y Wong; S Kochwa
Journal:  Vox Sang       Date:  1974       Impact factor: 2.144

2.  Anti-C3d antiglobulin reagents. I. Characteristics of the anti-C3c and anti-C3d responses during hyperimmunization in rabbits.

Authors:  J A Moore; H Chaplin
Journal:  Transfusion       Date:  1974 Sep-Oct       Impact factor: 3.157

3.  Antigenic determinants of human beta-1c and beta-1g-globulins.

Authors:  C West; N C Davis; J Forristal; J Herbst; R Spitzer
Journal:  J Immunol       Date:  1966-04       Impact factor: 5.422

4.  Quantitative haemagglutination. 4. Effect of neuraminidase treatment on agglutination by blood group antibodies.

Authors:  T J Greenwalt; E A Steane
Journal:  Br J Haematol       Date:  1973-08       Impact factor: 6.998

5.  Antigenic determinants of C3 and C4 complement components on washed erythrocytes from normal persons.

Authors:  R E Rosenfield
Journal:  Transfusion       Date:  1978 Sep-Oct       Impact factor: 3.157

6.  Changes in antigenic properties of human C3 upon activation and conversion by trypsin.

Authors:  J L Molenaar; M A Müller; C P Engelfriet; K W Pondman
Journal:  J Immunol       Date:  1974-04       Impact factor: 5.422

7.  Instrumented PVP-augmented antiglobulin tests. I. Detection of allogeneic antibodies coating otherwise normal erythrocytes.

Authors:  P Burkart; R E Rosenfield; T C Hsu; K Y Wong; J Nusbacher; S H Shaikh; S Kochwa
Journal:  Vox Sang       Date:  1974       Impact factor: 2.144

8.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

9.  Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b.

Authors:  G D Ross; M J Polley; E M Rabellino; H M Grey
Journal:  J Exp Med       Date:  1973-10-01       Impact factor: 14.307

10.  Isolation of a fragment (C3a) of the third component of human complement containing anaphylatoxin and chemotactic activity and description of an anaphylatoxin inactivator of human serum.

Authors:  V A Bokisch; H J Müller-Eberhard; C G Cochrane
Journal:  J Exp Med       Date:  1969-05-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.